- 질문내용 -
Your account's overdrawn online essay scholarships Lilly earlier this year asked U.S. and European regulatorsto approve two new diabetes treatments. One, a once-weekly pillcalled dulaglutide that is a so-called GLP-1 agonist, wouldcompete with similar drugs sold by Novo Nordisk andBristol-Myers Squibb. Another, called empaglifozin, is amember of an emerging new family of oral treatments called SGLT2inhibitors that remove excess blood sugar through the urine.
|
|
